
    
      This is a 4-week randomized, open-label trial to investigate the efficacy and safety of
      loxoprofen sodium hydrogel patch (LX-P) versus loxoprofen sodium tablet (LX-T) in patients
      with active ankylosing spondylitis(AS). The trial includes 70 patients who are randomly
      assigned to either the LX-P group (LX-P 100 mg per day) or LX-T group (LX-T 60 mg t.i.d.) for
      4 weeks.
    
  